NasdaqGS:GERN

Stock Analysis Report

Executive Summary

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies.

Snowflake

Fundamentals

Flawless balance sheet with limited growth.


Similar Companies

Share Price & News

How has Geron's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.0%

GERN

3.8%

US Biotechs

2.3%

US Market


1 Year Return

-15.9%

GERN

-10.0%

US Biotechs

5.6%

US Market

Return vs Industry: GERN underperformed the US Biotechs industry which returned -10% over the past year.

Return vs Market: GERN underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

GERNIndustryMarket
7 Day5.0%3.8%2.3%
30 Day-2.6%-2.8%-1.0%
90 Day18.4%-2.6%-0.7%
1 Year-15.9%-15.9%-9.2%-10.0%7.9%5.6%
3 Year-28.8%-28.8%14.7%10.7%45.6%36.3%
5 Year-31.2%-31.2%2.2%-2.8%65.8%47.6%

Price Volatility Vs. Market

How volatile is Geron's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Geron undervalued compared to its fair value and its price relative to the market?

1.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate GERN's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate GERN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GERN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: GERN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate GERN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GERN is good value based on its PB Ratio (1.8x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Geron forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

2.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GERN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GERN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GERN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GERN's revenue (65.4% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: GERN's revenue (65.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if GERN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Geron performed over the past 5 years?

-3.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: GERN is unprofitable, and losses have increased over the past 5 years at a rate of -3.5% per year.

Accelerating Growth: Unable to compare GERN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GERN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (78.4%).


Return on Equity

High ROE: GERN has a negative Return on Equity (-23.68%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: GERN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: GERN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Geron's financial position?


Financial Position Analysis

Short Term Liabilities: GERN's short term assets ($154.8M) exceeds its short term liabilities ($9.2M)

Long Term Liabilities: GERN has no long term liabilities


Debt to Equity History and Analysis

Debt Level: GERN is debt free.

Reducing Debt: GERN has not had any debt for past 5 years.


Balance Sheet

Inventory Level: GERN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if GERN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GERN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: GERN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -9.8% each year


Next Steps

Dividend

What is Geron's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate GERN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GERN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if GERN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GERN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GERN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Geron's salary, the management and board of directors tenure and is there insider trading?

6.8yrs

Average management tenure


CEO

Chip Scarlett (68yo)

8.1yrs

Tenure

US$2,772,509

Compensation

Dr. John A. Scarlett, also known as Chip, M.D., has been the Chief Executive Officer of Geron Corporation since joining in September 2011 and its President since January 5, 2012. Dr. Scarlett is Chairman o ...


CEO Compensation Analysis

Compensation vs. Market: Chip's total compensation ($USD2.77M) is above average for companies of similar size in the US market ($USD1.18M).

Compensation vs Earnings: Chip's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

6.8yrs

Average Tenure

55yo

Average Age

Experienced Management: GERN's management team is seasoned and experienced (6.8 years average tenure).


Board Age and Tenure

0.8yrs

Average Tenure

67yo

Average Age

Experienced Board: GERN's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Stephen Rosenfield (69yo)

    Executive VP

    • Tenure: 7.8yrs
    • Compensation: US$1.01m
  • Melissa A. Behrs (55yo)

    Executive VP & Chief Business Officer

    • Tenure: 12.8yrs
    • Compensation: US$1.11m
  • Chip Scarlett (68yo)

    CEO, President & Chairman of the Board

    • Tenure: 8.1yrs
    • Compensation: US$2.77m
  • Andrew Grethlein (55yo)

    Executive VP & COO

    • Tenure: 0.8yrs
    • Compensation: US$1.15m
  • Olivia Bloom (50yo)

    Executive VP of Finance

    • Tenure: 6.8yrs
    • Compensation: US$1.22m
  • Suzanne Messere

    Head of Investor Relations & Corporate Communications

    • Tenure: 0yrs
  • Aleksandra Rizo (44yo)

    Executive VP & Chief Medical Officer

    • Tenure: 0.8yrs
  • Shannon Odam

    Vice President of Human Resources

    • Tenure: 0.3yrs

Board Members

  • Karin Eastham (70yo)

    Lead Independent Director

    • Tenure: 0.8yrs
    • Compensation: US$239.40k
  • V. Lawlis (67yo)

    Independent Director

    • Tenure: 7.6yrs
    • Compensation: US$226.90k
  • Chip Scarlett (68yo)

    CEO, President & Chairman of the Board

    • Tenure: 8.1yrs
    • Compensation: US$2.77m
  • Bob Spiegel (70yo)

    Independent Director

    • Tenure: 9.4yrs
    • Compensation: US$221.90k
  • Susan Molineaux (65yo)

    Independent Director

    • Tenure: 7.1yrs
    • Compensation: US$216.90k
  • Dawn Bir (48yo)

    Independent Director

    • Tenure: 0.6yrs
  • Elizabeth O'Farrell (55yo)

    Independent Director

    • Tenure: 0.6yrs

Company Information

Geron Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Geron Corporation
  • Ticker: GERN
  • Exchange: NasdaqGS
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$278.866m
  • Shares outstanding: 188.42m
  • Website: https://www.geron.com

Number of Employees


Location

  • Geron Corporation
  • 149 Commonwealth Drive
  • Suite 2070
  • Menlo Park
  • California
  • 94025
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GERNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJul 1996
GONDB (Deutsche Boerse AG)YesCommon StockDEEURJul 1996
0IV3LSE (London Stock Exchange)YesCommon StockGBUSDJul 1996

Biography

Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage devel ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 23:36
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.